# A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

> **NCT07629960** · PHASE1,PHASE2 · RECRUITING · sponsor: **Blueprint Medicines Corporation** · enrollment: 265 (estimated)

## Conditions studied

- Advanced Solid Tumor
- Non-Small Cell Lung Cancer
- Colorectal Neoplasms
- Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** BLU-924

## Key facts

- **NCT ID:** NCT07629960
- **Lead sponsor:** Blueprint Medicines Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-04
- **Primary completion:** 2029-09
- **Final completion:** 2031-07
- **Target enrollment:** 265 (ESTIMATED)
- **Last updated:** 2026-09-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07629960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07629960, "A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07629960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*